Moyamoya vasculopathy - Patient demographics and characteristics in the Finnish population.
Background and purpose Moyamoya vasculopathy, a rare steno-occlusive progressive cerebrovascular disorder, has not been thoroughly studied in Caucasian populations. We established a registry of Finnish patients treated at the Helsinki University Hospital, to collect and report demographic and clinical data. Methods We collected data both retrospectively and prospectively from all the patients with a moyamoya vasculopathy referred to our hospital between January 1987 and December 2014. All patients underwent a neurological outpatient clinic visit. Results We diagnosed 61 patients (50 females, 10 children) with moyamoya vasculopathy. The mean age at the disease-onset was 31.5 ± 17.9 years. The two most common presenting symptoms were ischemic stroke (n = 31) and hemorrhage (n = 8). Forty-four percent underwent revascularization surgery, and 70% were prescribed antithrombotic treatment. Conclusions The results support in part the Western phenotype of the disease considering the later presentation and larger female predominance compared to the Asian moyamoya vasculopathy reports. However, the proportion of ischemic strokes and hemorrhagic strokes is closer to Japanese population than German population. The absence of familial cases points to a different genetic profile in the Finnish patients.
1 Clinical Neurosciences, Neurology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Marika
M
Saarela
1 Clinical Neurosciences, Neurology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Satu
S
Mustanoja
2 Department of Radiology, HUS Medical Imaging Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.
Johanna
J
Pekkola
3 Department of Child Neurology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.
Tiina
T
Tyni
4 Clinical Neurosciences, Neurosurgery, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Juha
J
Hernesniemi
4 Clinical Neurosciences, Neurosurgery, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Leena
L
Kivipelto
1 Clinical Neurosciences, Neurology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.|5 Institute of Neuroscience and Physiology, Sahlgrenska Academy at University of Gothenburg and Department of Neurology, Sahlgrenska University Hospital, Gothenburg, Sweden.
Turgut
T
Tatlisumak
D000293:Adolescent; D000328:Adult; D017668:Age of Onset; D000368:Aged; D000991:Antithrombins / Q000627:therapeutic use; D002545:Brain Ischemia / Q000453:epidemiology / Q000628:therapy; D002548:Cerebral Revascularization; D002648:Child; D002675:Child, Preschool; D005260:Female; D005387:Finland / Q000453:epidemiology; D006801:Humans; D020300:Intracranial Hemorrhages / Q000453:epidemiology / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009072:Moyamoya Disease / Q000453:epidemiology* / Q000628:therapy; D010641:Phenotype; D011446:Prospective Studies; D012042:Registries; D012189:Retrospective Studies; D012737:Sex Factors; D020521:Stroke / Q000453:epidemiology / Q000628:therapy; D055815:Young Adult
D000991:Antithrombins
Moyamoya; clinical characteristics; epidemiology; hemorrhagic stroke; ischemic stroke; vasculopathy